| Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
Nodes: 1975,
Authors: 5409,
Journals: 512,
Outer References: 13295,
Words: 3300
Collection span: 1980 - 2004
View: Overview. Sorted by journal name.
Page 4: 1 2 3 4 5 6 7
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
|---|---|---|---|---|---|
| 901 | 0 | 0 | 112 1984 CLINICAL RESEARCH 32(2):A569-A569 ARONSON IK; YU R; WEST DP; VANDENBROEK H; ANTEL J THALIDOMIDE INDUCED PERIPHERAL NEUROPATHY - EFFECT OF SERUM FACTOR ON NERVE CULTURES | 0 | 0 |
| 902 | 0 | 0 | 113 1984 CLINICAL RESEARCH 32(2):A603-A603 MILLIKAN LE; DOLL NJ; BARNHILL RL; HASTINGS RC; SALVAGGIO JE THE INVITRO EFFECTS OF THALIDOMIDE ON HUMAN POLYMORPHONUCLEAR LEUKOCYTE FUNCTION | 0 | 0 |
| 903 | 0 | 0 | 360 1993 CLINICAL RESEARCH 41(2):A496-A496 HARLAND CC; STEVENTON GB; MARSDEN JR THALIDOMIDE INDUCED NEUROPATHY AND DRUG METABOLIC POLYMORPHISM | 1 | 1 |
| 904 | 0 | 0 | 401 1994 CLINICAL RESEARCH 42(2):A142-A142 RIFKIN IR; MCHUGH SM; BRADLEY JR; THIRU S; EWAN PW; LOCKWOOD CM INDUCTION OF TH2, AND INHIBITION OF TH1, LYMPHOCYTE-RESPONSES BY THALIDOMIDE | 0 | 0 |
| 905 | 0 | 0 | 181 1986 CLINICAL RHEUMATOLOGY 5(3):365-371 HAMZA MH TREATMENT OF BEHCETS-DISEASE WITH THALIDOMIDE | 21 | 40 |
| 906 | 0 | 0 | 206 1987 CLINICAL RHEUMATOLOGY 6(4):608-609 HAMZA M; HAMZAOUI K; AYED K; ELEUCH M; ZRIBI A THALIDOMIDE AND CELL-MEDIATED IMMUNITY IN BEHCETS-DISEASE | 0 | 2 |
| 907 | 1 | 17 | 796 1999 CLINICAL THERAPEUTICS 21(2):319-330 Zeldis JB; Williams BA; Thomas SD; Elsayed ME STEPS (TM): A comprehensive program for controlling and monitoring access to thalidomide | 39 | 47 |
| 908 | 156 | 221 | 1706 2003 CLINICAL THERAPEUTICS 25(2):342-395 Matthews SJ; McCoy C Thalidomide: A review of approved and investigational uses | 2 | 6 |
| 909 | 51 | 221 | 964 2000 CLINICS IN DERMATOLOGY 18(1):131-145 Sanchez MR Miscellaneous treatments: Thalidomide, potassium iodide, levamisole, clofazimine, colchicine, and D-penicillamine | 0 | 3 |
| 910 | 1 | 35 | 182 1986 CLINICS IN PERINATOLOGY 13(3):555-573 NEWMAN CGH THE THALIDOMIDE SYNDROME - RISKS OF EXPOSURE AND SPECTRUM OF MALFORMATIONS | 6 | 19 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 911 | 1 | 236 | 596 1997 COLUMBIA LAW REVIEW 97(7):2153-2176 Bernstein A Formed by thalidomide: Mass torts as a false cure for toxic exposure | 1 | 6 |
| 912 | 57 | 82 | 1432 2002 CRITICAL REVIEWS IN IMMUNOLOGY 22(5-6):425-437 Dredge K; Marriott JB; Dalgleish AG Immunological effects of thalidomide and its chemical and functional analogs | 0 | 2 |
| 913 | 49 | 86 | 1707 2003 CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 46:S49-S57 Macpherson GR; Franks M; Tomoaia-Cotisel A; Ando Y; Price DK; Figg WD Current status of thalidomide and its role in the treatment of metastatic prostate cancer | 1 | 2 |
| 914 | 13 | 38 | 1708 2003 CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 46:S59-S65 Amato RJ Thalidomide therapy for renal cell carcinoma | 0 | 1 |
| 915 | 58 | 107 | 1433 2002 CROATIAN MEDICAL JOURNAL 43(3):274-285 Mujagic H; Chabner BA; Mujagic Z Mechanisms of action and potential therapeutic uses of thalidomide | 1 | 2 |
| 916 | 1 | 33 | 183 1986 CURRENT CONTENTS (50):3-11 GARFIELD E TERATOLOGY LITERATURE AND THE THALIDOMIDE CONTROVERSY | 0 | 0 |
| 917 | 3 | 44 | 797 1999 CURRENT EYE RESEARCH 19(6):483-490 Spraul CW; Kaven C; Kampmeier J; Lang GK; Lang GE Effect of thalidomide, octreotide, and prednisolone on the migration and proliferation of RPE cells in vitro | 5 | 9 |
| 918 | 22 | 80 | 694 1998 CURRENT MEDICINAL CHEMISTRY 5(3):163-178 Hashimoto Y Novel biological response modifiers derived from thalidomide | 16 | 38 |
| 919 | 40 | 59 | 1709 2003 CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT 6(1):92-99 Meierhofer C; Wiedermann CJ New insights into the pharmacological and toxicological effects of thalidomide | 3 | 3 |
| 920 | 45 | 95 | 965 2000 CURRENT OPINION IN ONCOLOGY 12(6):564-573 Thomas DA; Kantarjian HM Current role of thalidomide in cancer treatment | 16 | 41 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 921 | 26 | 123 | 1176 2001 CURRENT OPINION IN ONCOLOGY 13(5):374-381 Krown SE Management of Kaposi sarcoma: the role of interferon and thalidomide | 2 | 17 |
| 922 | 33 | 53 | 1434 2002 CURRENT OPINION IN ONCOLOGY 14(6):635-640 Raje N; Anderson KC Thalidomide and immunomodulatory drugs as cancer therapy | 8 | 14 |
| 923 | 10 | 29 | 1891 2004 CYTOKINE 26(4):145-148 Rosinol L; Cibeira MT; Segarra M; Cid MC; Filella X; Aymerich M; Rozman M; Arenillas L; Esteve J; Blade J; Montserrat E Response to thalidomide in multiple myeloma: impact of angiogenic factors | 0 | 0 |
| 924 | 92 | 115 | 1177 2001 DERMATOLOGIC CLINICS 19(1):87-+ Radomsky CL; Levine N Thalidomide | 4 | 8 |
| 925 | 0 | 5 | 11 1981 DERMATOLOGICA 162(2):86-90 SHESKIN J; GORODETZKY R; LOEWINGER E; WEINREB A INVIVO MEASUREMENTS OF IRON, COPPER AND ZINC IN THE SKIN OF PRURIGO NODULARIS PATIENTS TREATED WITH THALIDOMIDE | 3 | 11 |
| 926 | 0 | 7 | 12 1981 DERMATOLOGICA 163(2):145-150 SHESKIN J; GORODETSKY R; WEINREB A; LOEWINGER E IRON CONTENT OF SKIN BEFORE AND AFTER THALIDOMIDE TREATMENT OF LEPRA REACTION - A PRELIMINARY-REPORT | 0 | 5 |
| 927 | 0 | 39 | 44 1982 DERMATOLOGICA 165(4):355-362 SCOLARI F; HARMS M; GILARDI S THALIDOMIDE IN THE TREATMENT OF CHRONIC LUPUS-ERYTHEMATOSUS | 7 | 9 |
| 928 | 2 | 17 | 114 1984 DERMATOLOGICA 168(4):182-188 GENVO MF; FAURE M; THIVOLET J THALIDOMIDE AND THALIDOMIDE WITH COLCHICINE IN THE TREATMENT OF APHTHOSIS, RECURRENT MUCOCUTANEOUS APHTHAE AND BEHCETS-DISEASE | 8 | 16 |
| 929 | 2 | 5 | 231 1988 DERMATOLOGICA 176(2):107-107 VIRABEN R; DUPRE A ERYTHEMA-NODOSUM FOLLOWING THALIDOMIDE THERAPY FOR BEHCET DISEASE | 1 | 5 |
| 930 | 14 | 22 | 402 1994 DERMATOLOGY 189(2):179-181 BIELSA I; TEIXIDO J; RIBERA M; FERRANDIZ C ERYTHRODERMA DUE TO THALIDOMIDE - REPORT OF 2 CASES | 13 | 17 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 931 | 7 | 9 | 521 1996 DERMATOLOGY 193(4):321-323 Bonnetblanc JM; Royer C; Bedane C Thalidomide and recurrent aphthous stomatitis: A follow-up study | 5 | 10 |
| 932 | 1 | 8 | 597 1997 DERMATOLOGY 195(4):359-361 Ferrandiz C; Carrascosa JM; Just M; Bielsa I; Ribera M Sequential combined therapy with thalidomide and narrow-band (TLO1) UVB in the treatment of prurigo nodularis | 9 | 12 |
| 933 | 2 | 5 | 798 1999 DERMATOLOGY 199(2):195-195 Bez C; Lodi G; Sardella A; Della Volpe A; Carrassi A Oral lichenoid lesions after thalidomide treatment | 5 | 5 |
| 934 | 10 | 26 | 1435 2002 DERMATOLOGY 204(4):365-367 Nijsten T; Meuleman L; Schroyens W; Lambert J Thalidomide-induced morbilliform rash: Diagnosis and continuation of therapy, premedicated with methylprednisolone | 0 | 0 |
| 935 | 11 | 18 | 1710 2003 DERMATOLOGY 206(4):381-383 Kolivras A; De Maubeuge J; Andre J; Song M Thalidomide in refractory vulvar ulcerations associated with Crohn's disease | 1 | 1 |
| 936 | 12 | 17 | 1892 2004 DERMATOLOGY 208(2):149-152 Sander CS; Kaatz M; Elsner P Successful treatment of cutaneous Langerhans cell histiocytosis with thalidomide | 0 | 0 |
| 937 | 0 | 0 | 207 1987 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 112(9):365-365 LENZ W THALIDOMIDE-CAUSED BIRTH-DEFECTS | 0 | 0 |
| 938 | 0 | 16 | 272 1990 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 115(25):977-979 BROCHELER J; HALFMANN R ANTERIOR SACRAL MENINGOCELE ASSOCIATED WITH THALIDOMIDE EMBRYOPATHY | 0 | 0 |
| 939 | 0 | 0 | 966 2000 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 125:S26-S27 Eichhorn A; Kirch W Thalidomide for Behcets syndrome | 0 | 0 |
| 940 | 30 | 49 | 1178 2001 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 126(42):1178-1182 Tuinmann G; Hegewisch-Becker S; Hossfeld DK New indications for thalidomide | 2 | 3 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 941 | 3 | 26 | 1179 2001 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 126(42):1183-1186 Maio G On the history of the Contergan (thalidomide) catastrophe in the light of drug legislation | 0 | 3 |
| 942 | 6 | 6 | 1436 2002 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 127(15):818-818 Mensing H New indication for thalidomide? | 0 | 0 |
| 943 | 1 | 10 | 45 1982 DEVELOPMENT GROWTH & DIFFERENTIATION 24(2):217-222 MCBRIDE WG; STOKES PA; VARDY PH MATERNAL THALIDOMIDE TREATMENT AND CELL-DIVISION IN CULTURED RABBIT EMBRYOS - AUTOMATED IMAGE-ANALYSIS OF AUTORADIOGRAPHS | 2 | 2 |
| 944 | 3 | 34 | 82 1983 DEVELOPMENT GROWTH & DIFFERENTIATION 25(4):361-373 MCBRIDE WG; VARDY PH PATHOGENESIS OF THALIDOMIDE TERATOGENESIS IN THE MARMOSET (CALLITHRIX-JACCHUS) - EVIDENCE SUGGESTING A POSSIBLE TROPHIC INFLUENCE OF CHOLINERGIC NERVES IN LIMB MORPHOGENESIS | 1 | 6 |
| 945 | 11 | 39 | 522 1996 DEVELOPMENT GROWTH & DIFFERENTIATION 38(1):47-57 Audit CO; Eger K; Aimar C Possible involvement of an acylation mechanism in thalidomide-induced teratogenesis of the newt (Pleurodeles waltl) | 2 | 2 |
| 946 | 0 | 0 | 967 2000 DEVELOPMENTAL DYNAMICS 219(3):443-443 Fillmore BJ; Stephens TD Angiogenic integrin avb3 as a site of the teratogenic action of thalidomide | 0 | 0 |
| 947 | 6 | 38 | 1437 2002 DEVELOPMENTAL DYNAMICS 225(2):186-194 Hansen JM; Gong SG; Philbert M; Harris C Misregulation of gene expression in the redox-sensitive NF-kappa B-dependent limb outgrowth pathway by thalidomide | 1 | 3 |
| 948 | 2 | 19 | 403 1994 DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY 36(4):351-356 STROMLAND K; NORDIN V; MILLER M; AKERSTROM B; GILLBERG C AUTISM IN THALIDOMIDE EMBRYOPATHY - A POPULATION STUDY | 3 | 71 |
| 949 | 0 | 0 | 968 2000 DIABETES 49:A434-A434 Iqbal N; Boden G Thalidomide impairs insulin stimulated glucose uptake in patients with type 2 diabetes (T2DM) by inhibiting glycogen synthesis | 0 | 0 |
| 950 | 0 | 0 | 1180 2001 DIABETES 50:A473-A473 Bosco A; Lerario AC; Santos RF; Ferreira A; Ursich MJ; Silva ME; Rocha DM; Wajchenberg BL Study of Thalidomide and Rosiglitazone effects on the prevention of diabetic retinopathy of Streptozotocin diabetic rats | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 951 | 7 | 23 | 969 2000 DIABETES CARE 23(8):1172-1176 Iqbal N; Zayed M; Boden G Thalidomide impairs insulin action on glucose uptake and glycogen synthesis in patients with type 2 diabetes | 3 | 3 |
| 952 | 2 | 3 | 1711 2003 DIABETES CARE 26(4):1322-1323 Pathak RD; Jayaraj K; Blonde L Thalidomide-associated hyperglycemia and diabetes - Case report and review of literature | 0 | 0 |
| 953 | 6 | 42 | 1712 2003 DIABETOLOGIA 46(12):1669-1675 Bosco AA; Lerario AC; Santos RF; Wajchenberg BL Effect of thalidomide and rosiglitazone on the prevention of diabetic retinopathy in streptozotocin-induced diabetic rats | 1 | 1 |
| 954 | 1 | 1 | 1893 2004 DIABETOLOGIA 47(5):963-963 Bosco AA; Lerario AC; Santos RF; Wajchenberg BL Effect of thalidomide and rosiglitazone on the prevention of diabetic retinopathy in streptozotocin-induced diabetic rats (vol 46, pg 1669, 2003) | 0 | 0 |
| 955 | 0 | 7 | 273 1990 DICP-THE ANNALS OF PHARMACOTHERAPY 24(5):482-483 JEW LJ; MIDDLETON RK THALIDOMIDE IN ERYTHEMA-NODOSUM LEPROSUM | 0 | 0 |
| 956 | 4 | 13 | 274 1990 DICP-THE ANNALS OF PHARMACOTHERAPY 24(11):1054-1056 NICOLAU DP; WEST TE THALIDOMIDE - TREATMENT OF SEVERE RECURRENT APHTHOUS STOMATITIS IN PATIENTS WITH AIDS | 9 | 17 |
| 957 | 5 | 10 | 451 1995 DIGESTIVE DISEASES AND SCIENCES 40(5):1147-1148 NAUM SM; MOLLOY PJ; KANIA RJ; MCGARR J; VANTHIEL DH USE OF THALIDOMIDE IN TREATMENT AND MAINTENANCE OF IDIOPATHIC ESOPHAGEAL ULCERS IN HIV+ INDIVIDUALS | 7 | 11 |
| 958 | 14 | 63 | 1181 2001 DRUG DEVELOPMENT RESEARCH 54(4):209-218 Fernandez-Martinez E; Morales-Rios MS; Perez-Alvarez V; Muriel P Effects of thalidomide and 3-phthalimido-3-(3,4-dimethoxyphenyl)-propanamide on bile duct obstruction-induced cirrhosis in the rat | 2 | 3 |
| 959 | 9 | 24 | 257 1989 DRUG METABOLISM AND DISPOSITION 17(4):402-405 CHEN TL; VOGELSANG GB; PETTY BG; BRUNDRETT RB; NOE DA; SANTOS GW; COLVIN OM PLASMA PHARMACOKINETICS AND URINARY-EXCRETION OF THALIDOMIDE AFTER ORAL DOSING IN HEALTHY MALE-VOLUNTEERS | 77 | 81 |
| 960 | 8 | 13 | 1182 2001 DRUG METABOLISM AND DISPOSITION 29(10):1355-1357 Teo SK; Harden JL; Burke AB; Noormohamed FH; Youle M; Johnson MA; Peters BS; Stirling DI; Thomas SD Thalidomide is distributed into human semen after oral dosing | 8 | 13 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 961 | 16 | 37 | 1713 2003 DRUG METABOLISM AND DISPOSITION 31(4):469-475 Miyata M; Tamura E; Motoki K; Nagata K; Yamazoe Y Thalidomide-induced suppression of embryo fibroblast proliferation requires CYP1A1-mediated activation | 2 | 2 |
| 962 | 5 | 10 | 1714 2003 DRUG METABOLISM AND DISPOSITION 31(8):1072-1072 Zhou SF CYP1A1-mediated activation of thalidomide and suppression of embryo fibroblast proliferation | 0 | 0 |
| 963 | 0 | 0 | 1715 2003 DRUG METABOLISM AND DISPOSITION 31(8):1072-1072 Miyata M CYP1A1-mediated activation of thalidomide and suppression of embryo fibroblast proliferation - Reply | 0 | 0 |
| 964 | 0 | 0 | 1438 2002 DRUG METABOLISM REVIEWS 34:148-148 Zhou SF; Li Y; Kestell P; Paxton JW Preliminary study of thalidomide transport by the human intestinal cell line Caco-2 | 0 | 0 |
| 965 | 0 | 0 | 598 1997 DRUG NEWS & PERSPECTIVES 10(8):506-506 [Anon] Celgene's thalidomide approvable for ENL | 0 | 0 |
| 966 | 0 | 0 | 970 2000 DRUG NEWS & PERSPECTIVES 13(3):146-146 [Anon] Celgene's IMiDS and thalidomide show activity as COX-2 inhibitors | 1 | 0 |
| 967 | 3 | 34 | 1439 2002 DRUG NEWS & PERSPECTIVES 15(9):604-611 Botting J The history of thalidomide | 0 | 1 |
| 968 | 0 | 0 | 320 1992 DRUG SAFETY 7(2):116-134 GUNZLER V THALIDOMIDE IN HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) PATIENTS - A REVIEW OF SAFETY CONSIDERATIONS | 59 | 75 |
| 969 | 0 | 0 | 452 1995 DRUG SAFETY 12(6):364-369 SCHULER U; EHNINGER G THALIDOMIDE - RATIONALE FOR RENEWED USE IN IMMUNOLOGICAL DISORDERS | 25 | 36 |
| 970 | 9 | 10 | 695 1998 DRUG SAFETY 19(5):339-341 Smithells D Does thalidomide cause second generation birth defects? | 5 | 5 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 971 | 9 | 23 | 799 1999 DRUG SAFETY 21(3):161-169 Lary JM; Daniel KL; Erickson JD; Roberts HE; Moore CA The return of thalidomide - Can birth defects be prevented? | 5 | 10 |
| 972 | 44 | 140 | 1183 2001 DRUG SAFETY 24(2):87-117 Clark TE; Edom N; Larson J; Lindsey LJ Thalomid (R) (Thalidomide) capsules - A review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing | 11 | 14 |
| 973 | 12 | 70 | 800 1999 DRUGS 58(6):953-963 Ravot E; Lisziewicz J; Lori F New uses for old drugs in HIV infection - The role of hydroxyurea, cyclosporin and thalidomide | 3 | 15 |
| 974 | 41 | 120 | 971 2000 DRUGS 60(2):273-292 Peuckmann V; Fisch M; Bruera E Potential novel uses of thalidomide - Focus on palliative care | 27 | 40 |
| 975 | 44 | 67 | 1184 2001 DRUGS 61(6):777-787 Bousvaros A; Mueller B Thalidomide in gastrointestinal disorders | 4 | 8 |
| 976 | 102 | 164 | 1440 2002 DRUGS & AGING 19(2):85-100 Zhou SF; Kestell P; Tingle MD; Paxton JW Thalidomide in cancer treatment - A potential role in the elderly? | 4 | 5 |
| 977 | 16 | 47 | 1185 2001 DRUGS OF THE FUTURE 26(1):100-103 [Anon] Thalidomide - Synovir (R) - Thalomid (R) - Talizer (R) - Oncolytic treatment of IBD antiarthritic treatment of leprosy | 0 | 0 |
| 978 | 8 | 28 | 1894 2004 DRUGS OF THE FUTURE 29(4):383-391 Hashimoto Y; Tanatani A; Nagasawa K; Miyachi H Thalidomide as a multitarget drug and its application as a template for drug design | 0 | 0 |
| 979 | 24 | 52 | 1895 2004 DRUGS OF TODAY 40(3):197-204 Joglekar S; Levin M The promise of thalidomide: Evolving indications | 0 | 0 |
| 980 | 0 | 0 | 46 1982 EEG-EMG-ZEITSCHRIFT FUR ELEKTROENZEPHALOGRAPHIE ELEKTROMYOGRAPHIE UND VERWANDTE GEBIETE 13(4):167-170 LUDOLPH A; MATZ DR ELECTRONEUROGRAPHIC STUDIES IN PATIENTS UNDER THALIDOMIDE THERAPY OF LUPUS ERYTHEMATODES DISCOIDES | 6 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 981 | 0 | 0 | 13 1981 ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY 52(3):S7-S7 LIPINSKI CG; WEISSER J PATHOLOGICAL EEG FINDINGS IN ADOLESCENTS WITH SEVERE SEQUELAE AFTER THALIDOMIDE EMBRYOPATHY | 0 | 0 |
| 982 | 0 | 0 | 83 1983 ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY 56(3):S128-S128 LUDOLPH A; SCHULTE J; BRUNE GG ELECTRO-PHYSIOLOGICAL STUDIES CONCERNING THE REVERSIBILITY OF POLYNEUROPATHIES DUE TO THALIDOMIDE THERAPY OF LUPUS ERYTHEMATODES DISCOIDES | 0 | 0 |
| 983 | 0 | 0 | 146 1985 ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY 61(3):S174-S174 KANNO O; KAZAMATSURI H ELECTROENCEPHALOGRAPHIC STUDY ON THALIDOMIDE EMBRYOPATHY | 0 | 0 |
| 984 | 1 | 2 | 184 1986 ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY 64(3):P66-P66 SMITH NJ; JENKINS JS; POWELL RJ; ALLEN BR; LITTLEWOOD SM; MAURICE PDL NERVE-CONDUCTION STUDIES IN PATIENTS TAKING THALIDOMIDE | 0 | 0 |
| 985 | 12 | 34 | 801 1999 ELECTROPHORESIS 20(12):2425-2431 Meyring M; Chankvetadze B; Blaschke G Enantioseparation of thalidomide and its hydroxylated metabolites using capillary electrophoresis with various cyclodextrins and their combinations as chiral buffer additives | 2 | 13 |
| 986 | 15 | 32 | 972 2000 ELECTROPHORESIS 21(15):3270-3279 Meyring M; Muhlenbrock C; Blaschke G Investigation of the stereoselective in vitro biotransformation of thalidomide using a dual cyclodextrin system in capillary electrophoresis | 7 | 17 |
| 987 | 7 | 46 | 1186 2001 ELECTROPHORESIS 22(15):3185-3190 Schoetz G; Trapp O; Schurig V Determination of the enantiomerization barrier of thalidomide by dynamic capillary electrokinetic chromatography | 1 | 4 |
| 988 | 1 | 5 | 523 1996 ENDOSCOPY 28(5):471-472 Louvel D; Musso S; Metivier S; Croizet O; Rouquet RM; Massip P; Escourrou J; Frexinos J Idiopathic esophageal ulceration associated with human immunodeficiency virus infection: Efficacy of thalidomide treatment | 0 | 1 |
| 989 | 0 | 0 | 453 1995 ENVIRONMENTAL HEALTH PERSPECTIVES 103(2):132-132 [Anon] RETHINKING THALIDOMIDE | 0 | 0 |
| 990 | 19 | 36 | 802 1999 ETHIOPIAN MEDICAL JOURNAL 37(4):275-280 Shannon EJ 24th Kellersberger Memorial Lecture, 1999 thalidomide: Will the past overshadow a promising future? | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 991 | 0 | 0 | 454 1995 EUROPEAN CHEMICAL NEWS 63(1667):8-8 [Anon] GUINNESS TOPS UP THALIDOMIDE FUND | 0 | 0 |
| 992 | 0 | 0 | 599 1997 EUROPEAN CHEMICAL NEWS 68(1780):51-51 [Anon] Celgene - FDA approves thalidomide's use against ENL | 0 | 0 |
| 993 | 0 | 0 | 696 1998 EUROPEAN CYTOKINE NETWORK 9(3):367-367 Corral LG; Haslett PAJ; Ocampo C; Muller GW; Wong ML; Stirling D; Kaplan G Two distinct classes of thalidomide analogues which shape potent TNF-alpha inhibitory activity, modulate other cytokines differently | 0 | 0 |
| 994 | 7 | 20 | 973 2000 EUROPEAN CYTOKINE NETWORK 11(4):574-579 van Crevel R; Vonk AG; Netea MG; Kullberg BJ; van der Meer JWM Modulation of LPS-, PHA-and M-tuberculosis-mediated cytokine production by pentoxifylline and thalidomide | 2 | 3 |
| 995 | 0 | 0 | 974 2000 EUROPEAN HEART JOURNAL 21:367-367 Vescovo G; Ceconi C; Ferrari R; Ambrosio GB; Ravara B; Angelini A; Corti A; Rossini K; Sandri M; Leprotti C; Dalla Libera L Does thalidomide block apoptosis and prevent from the development of skeletal muscle myopathy in chronic heart failure? | 0 | 0 |
| 996 | 1 | 1 | 1187 2001 EUROPEAN JOURNAL OF CANCER 37(16):1966-1966 [Anon] Thalidomide is back | 0 | 0 |
| 997 | 0 | 0 | 1441 2002 EUROPEAN JOURNAL OF CANCER 38:S53-S53 Villalona-Calero M; Duan W; Otterson G; Kleiber B; Hindman K; Shah M; Young D; Wu W; Kuhn J Thalidomide modulation of Irinotecan; an NF-kB dependent effect? | 0 | 0 |
| 998 | 0 | 0 | 1442 2002 EUROPEAN JOURNAL OF CANCER 38:S82-S82 Ng SSW; Kruger EA; Luzzio FA; Eger K; Guetschow M; Hauschildt S; Hecker T; Teubert U; Weiss M; Figg WD In vitro antiangiogenic activity of thalidomide analogues | 0 | 0 |
| 999 | 0 | 0 | 1716 2003 EUROPEAN JOURNAL OF CANCER 39(7):854-854 [Anon] Thalidomide on trial | 0 | 0 |
| 1000 | 9 | 31 | 455 1995 EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 49(1-2):1-6 HARLAND CC; STEVENTON GB; MARSDEN JR THALIDOMIDE INDUCED NEUROPATHY AND GENETIC-DIFFERENCES IN DRUG-METABOLISM | 20 | 23 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1001 | 59 | 87 | 1188 2001 EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 57(5):365-376 Eriksson T; Bjorkman S; Hoglund P Clinical pharmacology of thalidomide | 22 | 32 |
| 1002 | 11 | 33 | 404 1994 EUROPEAN JOURNAL OF DERMATOLOGY 4(1):9-15 OCHONISKY S; REVUZ J THALIDOMIDE USE IN DERMATOLOGY | 29 | 34 |
| 1003 | 14 | 24 | 524 1996 EUROPEAN JOURNAL OF DERMATOLOGY 6(5):373-376 Charue D; Chauvin E; Duguet C; Revuz J; Bagot M Thalidomide decreases the production of GM-CSF and TNF-alpha in the mixed epidermal cell-lymphocyte reaction | 1 | 2 |
| 1004 | 13 | 14 | 1443 2002 EUROPEAN JOURNAL OF DERMATOLOGY 12(1):63-65 Frances C; El Khoury S; Gompel A; Becherel PA; Chosidow O; Piette JC Transient secondary amenorrhea in women treated by thalidomide | 1 | 2 |
| 1005 | 2 | 14 | 525 1996 EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY 8(9):929-931 Postema PTE; denHaan P; vanHagen PM; vanBlankenstein M Treatment of colitis in Behcet's disease with thalidomide | 12 | 20 |
| 1006 | 12 | 33 | 1717 2003 EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY 15(9):951-957 Muriel P; Fernandez-Martinez E; Perez-Alvarez V; Lara-Ochoa F; Ponce S; Garcia J; Shibayama M; Tsutsumi V Thalidomide ameliorates carbon tetrachloride induced cirrhosis in the rat | 0 | 1 |
| 1007 | 1 | 6 | 1718 2003 EUROPEAN JOURNAL OF HAEMATOLOGY 70(3):198-199 Vicari P; Ribas C; Sampaio M; Arantes AM; Yamamoto M; Reis JB; Segreto RA; Bordin JO; Colleoni GWB Can thalidomide be effective to treat plasma cell leptomeningeal infiltration? | 0 | 0 |
| 1008 | 16 | 28 | 1896 2004 EUROPEAN JOURNAL OF HAEMATOLOGY 72(1):52-57 Strupp C; Germing U; Scherer A; Kundgen A; Modder U; Gattermann N; Haas R Thalidomide for the treatment of idiopathic myelofibrosis | 0 | 0 |
| 1009 | 15 | 30 | 1897 2004 EUROPEAN JOURNAL OF HAEMATOLOGY 72(6):403-409 Offidani M; Corvatta L; Marconi M; Malerba L; Mele A; Olivieri A; Brunori M; Catarini M; Candela M; Capelli D; Montanari M; Rupoli S; Leoni P Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy | 0 | 0 |
| 1010 | 11 | 26 | 1898 2004 EUROPEAN JOURNAL OF HAEMATOLOGY 73(2):98-103 Tosi P; Zamagni E; Cellini C; Cangini D; Tacchetti P; Tura S; Baccarani M; Cavo M Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1011 | 5 | 25 | 1444 2002 EUROPEAN JOURNAL OF HEART FAILURE 4(4):455-460 Vescovo G; Ravara B; Angelini A; Sandri M; Carraro U; Ceconi C; Libera LD Effect of thalidomide on the skeletal muscle in experimental heart failure | 1 | 2 |
| 1012 | 0 | 13 | 14 1981 EUROPEAN JOURNAL OF PEDIATRICS 136(3):229-230 BURGIO GR THE THALIDOMIDE DISASTER BRIEFLY REVISITED | 3 | 4 |
| 1013 | 0 | 16 | 47 1982 EUROPEAN JOURNAL OF PEDIATRICS 138(1):77-80 VANREGEMORTER N; HAUMONT D; KIRKPATRICK C; VISEUR P; JEANTY P; DODION J; MILAIRE J; ROOZE M; RODESCH F HOLT ORAM SYNDROME MISTAKEN FOR THALIDOMIDE EMBRYOPATHY - EMBRYOLOGICAL CONSIDERATIONS | 1 | 6 |
| 1014 | 0 | 38 | 208 1987 EUROPEAN JOURNAL OF PEDIATRICS 146(1):63-67 SCHAFER KH; KRAMER M INFANTILE HYPERTROPHIC PYLORIC-STENOSIS AFTER PRENATAL EXPOSURE TO THALIDOMIDE | 0 | 0 |
| 1015 | 4 | 22 | 1899 2004 EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 21(4):465-469 Abraham MH Hydrogen bond and other descriptors for thalidomide and its N-alkyl analogs; prediction of physicochemical and biological properties | 0 | 0 |
| 1016 | 0 | 42 | 147 1985 EUROPEAN JOURNAL OF PHARMACOLOGY 119(1-2):39-46 YOUDIM MBH; ASHKENAZI R SEROTONERGIC INVOLVEMENT IN PHARMACOLOGICAL ACTION OF THE ANXIOLYTIC-SEDATIVES THALIDOMIDE AND SUPIDIMIDE | 0 | 1 |
| 1017 | 10 | 34 | 975 2000 EUROPEAN JOURNAL OF PHARMACOLOGY 391(1-2):97-103 Ribeiro RA; Vale ML; Ferreira SH; Cunha FQ Analgesic effect of thalidomide on inflammatory pain | 3 | 18 |
| 1018 | 19 | 36 | 1445 2002 EUROPEAN JOURNAL OF PHARMACOLOGY 453(2-3):325-334 Thiele A; Bang R; Gutschow M; Rossol M; Loos S; Eger K; Tiegs G; Hauschildt S Cytokine modulation and suppression of liver injury by a novel analogue of thalidomide | 1 | 3 |
| 1019 | 8 | 23 | 1446 2002 EUROPEAN JOURNAL OF SURGERY 168(11):641-645 Mall JW; Schwenk W; Philipp AW; Muller JM; Pollmann C Thalidomide given intraperitoneally reduces the number of postoperative adhesions after large bowel resection in rabbits | 0 | 0 |
| 1020 | 8 | 14 | 275 1990 EUROPEAN SURGICAL RESEARCH 22(6):336-339 EMRE S; SUMRANI N; HONG J BENEFICIAL EFFECT OF THALIDOMIDE AND CICLOSPORIN COMBINATION IN HETEROTOPIC CARDIAC TRANSPLANTATION IN RATS | 5 | 5 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1021 | 0 | 8 | 148 1985 EXPERIMENTAL ANIMALS 34(3):295-302 MATSUBARA Y; MIKAMI T TERATOGENIC POTENTIALITY OF SINGLE DOSE OF THALIDOMIDE IN JW-NIBS RABBITS | 0 | 1 |
| 1022 | 0 | 37 | 1900 2004 EXPERIMENTAL BRAIN RESEARCH 156(3):333-341 Stoeckel MC; Pollok B; Schnitzler A; Witte OW; Seitz RJ Use-dependent cortical plasticity in thalidomide-induced upper extremity dysplasia: evidence from somaesthesia and neuroimaging | 0 | 0 |
| 1023 | 11 | 41 | 600 1997 EXPERIMENTAL EYE RESEARCH 64(6):971-978 Kenyon BM; Browne F; DAmato RJ Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization | 97 | 150 |
| 1024 | 0 | 0 | 209 1987 EXPERIMENTAL HEMATOLOGY 15(5):476-476 HULLIN R; VOGELSANG GB; BRUNDRETTE R; COLVIN OM; SANTOS GW; HESS AD INTRACELLULAR BINDING-PROTEINS FOR THALIDOMIDE | 0 | 0 |
| 1025 | 0 | 0 | 307 1991 EXPERIMENTAL HEMATOLOGY 19(6):553-553 VOGELSANG GB; BUJNOVSZKY C; BOUCHER C; LEONG K; JALALIAN M; HESS A; SANTOS GW INVITRO IMMUNOLOGICAL EFFECTS OF THALIDOMIDE | 0 | 0 |
| 1026 | 20 | 52 | 456 1995 EXPERIMENTAL HEMATOLOGY 23(9):978-985 FERNANDEZ LP; SCHLEGEL PG; BAKER J; CHEN YF; CHAO NJ DOES THALIDOMIDE AFFECT IL-2 RESPONSE AND PRODUCTION | 21 | 21 |
| 1027 | 1 | 1 | 457 1995 EXPERIMENTAL HEMATOLOGY 23(12):1324-1324 FERNANDEZ LP; SCHLEGEL PG; BAKER J; CHEN YF; CHAO NJ DOES THALIDOMIDE AFFECT IL-2 RESPONSE AND PRODUCTION (VOL 23, PG 978, 1995) | 1 | 1 |
| 1028 | 29 | 60 | 697 1998 EXPERIMENTAL HEMATOLOGY 26(3):217-221 Or R; Feferman R; Shoshan S Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs | 18 | 24 |
| 1029 | 0 | 0 | 976 2000 EXPERIMENTAL HEMATOLOGY 28(7):103-104 Raza A; Lisak L; Little L; Andrews C; Meyer P; Ekbal M; Venugopal P Improvement in cytopenias of patients with myelodysplastic syndromes (MDS) in response to thalidomide | 0 | 0 |
| 1030 | 0 | 0 | 977 2000 EXPERIMENTAL HEMATOLOGY 28(7):110-110 Janssen WE; Dalton WS Improved blood hematopoietic progenitor mobilization in myeloma patients following treatment with thalidomide | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1031 | 0 | 0 | 1447 2002 EXPERIMENTAL HEMATOLOGY 30(6):60-60 Biscardi M; Gavazzi S; Balestri F; Grossi A Angiogenic growth factors (VEGF, TGF-b1, bFGF) and thalidomide effect in myelofibrosis with myeloid metaplasia | 0 | 0 |
| 1032 | 0 | 0 | 1448 2002 EXPERIMENTAL HEMATOLOGY 30(6):98-98 Schey S; Jones R; Raj K; Streetley M A phase I study of an immunomodulatory thalidomide analogue (CC4047) in relapse/refractory multiple myeloma | 0 | 0 |
| 1033 | 0 | 0 | 1449 2002 EXPERIMENTAL HEMATOLOGY 30(6):98-98 Mohty M; Blaise D; Isnardon D; Olive D; Gaugler B Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide: implications for multiple myeloma therapy | 0 | 0 |
| 1034 | 0 | 0 | 1719 2003 EXPERIMENTAL HEMATOLOGY 31(7):198-198 Moutouh-De Parseval L; Glezer E; Corral L; Galliher A; Wu J; Brady H; Mercurio F; Chan K Immunomodulatory thalidomide analogs modulate hematopoietic stem cell developmental pathways | 0 | 0 |
| 1035 | 40 | 53 | 1189 2001 EXPERT OPINION ON BIOLOGICAL THERAPY 1(4):675-682 Marriott JB; Muller G; Stirling D; Dalgleish AG Immunotherapeutic and antitumour potential of thalidomide analogues | 12 | 16 |
| 1036 | 73 | 144 | 1720 2003 EXPERT OPINION ON INVESTIGATIONAL DRUGS 12(7):1211-1225 Fanelli M; Sarmiento R; Gattuso D; Carillio G; Capaccetti B; Vacca A; Roccaro AM; Gasparini G Thalidomide: a new anticancer drug? | 3 | 7 |
| 1037 | 40 | 78 | 1901 2004 EXPERT OPINION ON THERAPEUTIC PATENTS 14(2):215-229 Luzzio FA; Figg WD Thalidomide analogues: derivatives of an orphan drug with diverse biological activity | 0 | 0 |
| 1038 | 7 | 18 | 1450 2002 FARMACO 57(7):551-554 Blaschke G; Meyring M; Muhlenbrock C; Chankvetadze B Recent results of biotransformation of drugs: investigation of the in vitro biotransformation of thalidomide using a dual cyclodextrin system in capillary electrophoresis | 0 | 2 |
| 1039 | 0 | 0 | 526 1996 FASEB JOURNAL 10(6):303-303 Shannon EJ; Sandoval F; Krahenbuhl J Hydrolysis of thalidomide abrogates its ability to enhance IL-2 or to suppress TNF-alpha. | 0 | 0 |
| 1040 | 0 | 0 | 698 1998 FASEB JOURNAL 12(4):A262-A262 Rowland TL; McHugh SM; Ewan PW; Lachmann PJ; Dearman RJ; Kimber I Down-regulation of T-cell and non-T-cell derived tumor necrosis factor alpha by thalidomide and dexamethasone | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1041 | 0 | 0 | 978 2000 FASEB JOURNAL 14(8):A1512-A1512 Cornely KA; Bennett NS Thalidomide makes a comeback: A case study exercise that integrates biochemistry and organic chemistry | 0 | 0 |
| 1042 | 0 | 0 | 1190 2001 FASEB JOURNAL 15(4):A556-A556 Jajeh A; Boulos B; Youakim J; Ali M; Woynarowsky A In vitro reduction of accelerated apoptosis of neutrophils in blood drawn from an HIV positive subject with Thalidomide. | 0 | 0 |
| 1043 | 0 | 0 | 1721 2003 FASEB JOURNAL 17(7):C124-C124 Dredge K; Marriott JB; Todryk SM; Klaschka D; Horsfall R; Dalgleish A The role of thalidomide-related IMiDs in the induction of innate and adaptive anti-tumor immunity | 0 | 0 |
| 1044 | 0 | 0 | 1902 2004 FASEB JOURNAL 18(4):A68-A68 Segarra M; Lozano E; Vilardell C; Esparza J; Izco N; Blade J; Campo E; Cid MC Thalidomide (Thd) decreases Fibronectin (FN)-induced gelatinase (MMP-2 and MMP-9) production by B lymphoid cell lines | 0 | 0 |
| 1045 | 0 | 0 | 15 1981 FEDERATION PROCEEDINGS 40(3):668-668 GORDON GB; SPIELBERG SP; BLAKE DA; BALASUBRAMANIAN V THALIDOMIDE TERATOGENESIS - EVIDENCE FOR A TOXIC ARENE OXIDE METABOLITE | 0 | 0 |
| 1046 | 0 | 0 | 149 1985 FEDERATION PROCEEDINGS 44(6):1881-1881 VOGELSANG G; GORDON G; HORWITZ L; SANTOS G; HESS A IMMUNOSUPPRESSIVE ACTIVITY OF THALIDOMIDE | 0 | 2 |
| 1047 | 2 | 31 | 458 1995 FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY 12(3-4):165-174 GEIST C; WOHRMANN T; SCHNEIDER J; ZWINGENBERGER K EFFECTS OF THALIDOMIDE ON THE LOCAL SHWARTZMAN REACTION IN MICE AND RABBITS | 6 | 8 |
| 1048 | 0 | 0 | 1451 2002 FERTILITY AND STERILITY 77(2):S28-S28 Zhong S; Shen K; Lang J The effects of thalidomide on interleukin-6 and vascular endothelial growth factor expression of endometrial stromal cell in vitro. | 0 | 0 |
| 1049 | 0 | 0 | 1452 2002 FERTILITY AND STERILITY 78(3):S87-S87 Scarpellini F; Sbracia M; Lecchini S; Scarpellini L Anti-angiogenesis treatment with thalidomide in endometriosis: A pilot study. | 0 | 1 |
| 1050 | 8 | 13 | 1903 2004 FERTILITY AND STERILITY 82(2):460-462 Dharia SP; Steinkampf MP; Cater C Thalidomide-induced amenorrhea: case report and literature review | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1051 | 10 | 24 | 405 1994 FOLIA BIOLOGICA 40(4):161-171 BILA V; KREN V EVIDENCE FOR TERATOGENICITY OF THALIDOMIDE USING CONGENIC AND RECOMBINANT INBRED RAT STRAINS | 0 | 10 |
| 1052 | 0 | 3 | 185 1986 FOOD AND CHEMICAL TOXICOLOGY 24(6-7):635-636 NEWALL DR; TESH JM EMBRYO CULTURE AS AN EARLY SCREEN FOR TERATOGENIC POTENTIAL .2. THALIDOMIDE | 0 | 2 |
| 1053 | 4 | 28 | 186 1986 FOOD AND DRUG LAW JOURNAL 41(4):458-466 SHERMAN M; STRAUSS S THALIDOMIDE - A 25-YEAR PERSPECTIVE | 4 | 14 |
| 1054 | 0 | 0 | 601 1997 FORTUNE 136(6):36-& McLean B Thalidomide .2. | 0 | 0 |
| 1055 | 0 | 0 | 1191 2001 FREE RADICAL BIOLOGY AND MEDICINE 31:S54-S54 Hansen JM; Gong SG; Harris C Thalidomide (TD) depletes glutathione and alters gene expression in the developing limb. | 0 | 0 |
| 1056 | 4 | 11 | 232 1988 FUNDAMENTAL & CLINICAL PHARMACOLOGY 2(6):493-497 DESCOTES J; TEDONE R; EVREUX JC ENHANCEMENT OF ANTIBODY-RESPONSE AND DELAYED-TYPE HYPERSENSITIVITY BY THALIDOMIDE IN MICE | 3 | 3 |
| 1057 | 2 | 6 | 84 1983 GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE 7(8-9):751-751 COUZIGOU P; DOUTRE MS; HOUDEE G; RICHARDMOLARD B; FLUERY B; AMOURETTI M; BEYLOT C; BERAUD C THALIDOMIDE IN THE TREATMENT OF BEHCETS SYNDROME | 0 | 9 |
| 1058 | 0 | 2 | 115 1984 GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE 8(2):196-196 ROGE J; TESTAS P THALIDOMIDE IN BEHCETS SYNDROME | 6 | 7 |
| 1059 | 1 | 6 | 258 1989 GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE 13(1):104-104 PATEY O; CHARASZ N; ROUCAYROL AM; MALKIN JE; LAFAIX C THALIDOMIDE AND INTESTINAL INVOLVEMENT IN BEHCETS SYNDROME | 2 | 3 |
| 1060 | 5 | 5 | 459 1995 GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE 19(1):128-129 SIRE S; FRAISSE P; REY D; JACQUEMIN C; KEMPF G; PARTISANI M; LANG JM EFFECTIVENESS OF THALIDOMIDE IN THE TREATMENT OF ESOPHAGEAL ULCERS IN AIDS | 2 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1061 | 0 | 1 | 361 1993 GASTROENTEROLOGY 104(4):A683-A683 COHEN LB; PEAREN S; IAZZETTA J THALIDOMIDE FOR INFLAMMATORY BOWEL-DISEASE - A PRELIMINARY-REPORT | 0 | 0 |
| 1062 | 8 | 15 | 362 1993 GASTROENTEROLOGY 105(3):956-956 RHOTON AJ ROLE FOR THALIDOMIDE IN PRIMARY BILIARY-CIRRHOSIS TREATMENT | 0 | 0 |
| 1063 | 11 | 39 | 602 1997 GASTROENTEROLOGY 112(6):1823-1829 Sharpstone D; Rowbottom A; Francis N; Tovey G; Ellis D; Barrett M; Gazzard B Thalidomide: A novel therapy for microsporidiosis | 12 | 42 |
| 1064 | 0 | 0 | 699 1998 GASTROENTEROLOGY 114(4):A1008-A1008 Kenet G; Avni Y; Aeed H; Shirin H; Matas Z; Zaidel L; Galor S; Hershkovitz R; Bruck R Iodoacetamide-induced colitis in rats is inhibited by thalidomide. | 0 | 0 |
| 1065 | 0 | 0 | 803 1999 GASTROENTEROLOGY 116(4):A745-A745 Kane SV; Ehrenpreis ED; Cohen LB; Hanauer SB; Cohen RD Therapeutic efficacy of thalidomide for patients with refractory Crohn's disease (CD) | 2 | 5 |
| 1066 | 0 | 0 | 804 1999 GASTROENTEROLOGY 116(4):A767-A767 Macumber C; Wettstein AP; Vickers CR; Hing M; Edwards PD; Byrnes DJ; Meagher AP Thalidomide-effective therapy in chronic resistant inflammatory bowel disease. Department of gastroenterology. St. Vincent's Hospital, Sydney, Australia. | 2 | 3 |
| 1067 | 0 | 0 | 805 1999 GASTROENTEROLOGY 116(4):A837-A837 Vasiliauskas EA; Kam LY; Abreu-Martin MT; Papadakis KA; Zeldis JB; Targan SR An open-label, stepwise dose-escalating pilot study to evaluate the safety, tolerance, & efficacy of low-dose thalidomide in the treatment of chronically-active, steroid-department Crohn's disease (CD) | 3 | 0 |
| 1068 | 0 | 0 | 806 1999 GASTROENTEROLOGY 116(4):A843-A843 Wedel S; Bauditz J; Suk A; Lochs H Efficacy of thalidomide in Crohn's disease. | 2 | 3 |
| 1069 | 20 | 33 | 807 1999 GASTROENTEROLOGY 117(6):1271-1277 Ehrenpreis ED; Kane SV; Cohen LB; Cohen RD; Hanauer SB Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial | 44 | 132 |
| 1070 | 16 | 40 | 808 1999 GASTROENTEROLOGY 117(6):1278-1287 Vasiliauskas EA; Kam LY; Abreu-Martin MT; Hassard PV; Papadakis KA; Yang HY; Zeldis JB; Targan SR An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease | 43 | 129 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1071 | 22 | 32 | 809 1999 GASTROENTEROLOGY 117(6):1485-1488 Sands BE; Podolsky DK New life in a sleeper: Thalidomide and Crohn's disease | 8 | 25 |
| 1072 | 0 | 0 | 979 2000 GASTROENTEROLOGY 118(4):A580-A580 Bauditz L; Wedel S; Suk A; Lochs H Cytokine profiles under treatment with Thalidomide steroid-resistant Crohn's disease. | 0 | 0 |
| 1073 | 0 | 0 | 980 2000 GASTROENTEROLOGY 118(4):A582-A582 Kam LY; Vasiliauskas EA; Abreu MT; Hassard PV; Zeldis J; Targan SR Open labeled pilot study of thalidomide(thal) as a novel therapy for medically resistant ulcerative colitis (UC). | 1 | 6 |
| 1074 | 0 | 0 | 981 2000 GASTROENTEROLOGY 118(4):A586-A586 Prehn JL; Muller GW; Man HW; Stirling DJ; Targan SR Thalidomide analogs, but not thalidomide itself, are potent inhibitors of lamina propria mononuclear cell (LPMC) TNF-A and IFN-Gamma production in response to T cell stimuli. | 0 | 0 |
| 1075 | 4 | 8 | 982 2000 GASTROENTEROLOGY 119(2):596-596 Fishman SJ; Feins NR; D'Amato RJ; Folkman J Thalidomide therapy for Crohn's disease | 5 | 12 |
| 1076 | 0 | 0 | 1192 2001 GASTROENTEROLOGY 120(5):A278-A278 Stein DJ; Rafiee P; Taras A; Lamirand TH; Fisher PJ; Ogawa H; Telford GL; Otterson MF; Johnson CP; Binion DG Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC). | 0 | 0 |
| 1077 | 0 | 0 | 1193 2001 GASTROENTEROLOGY 120(5):A611-A612 Khan ZH; Cole AT; MacDonald I; Pye D; Austin A; Freeman JG The role of thalidomide in reversing cachexia in patients with inoperable oesophageal cancers | 0 | 0 |
| 1078 | 6 | 6 | 1194 2001 GASTROENTEROLOGY 120(6):1567-1568 Fox MR; Harris A Intractable insomnia after cessation of treatment with thalidomide | 3 | 3 |
| 1079 | 1 | 1 | 1195 2001 GASTROENTEROLOGY 121(3):747-747 Fox MR; Harris A Intractable insomnia after cessation of treatment with Thalidomide. (vol 120, pg 1567, 2001) | 0 | 0 |
| 1080 | 0 | 0 | 1453 2002 GASTROENTEROLOGY 122(4):A194-A194 Bauditz J; Wedel S; Lochs H Thalidomide for treatment of intestinal bleeding: Correlation to VEGF | 1 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1081 | 0 | 0 | 1454 2002 GASTROENTEROLOGY 122(4):A395-A395 Kim JW; Kim SG; Kim HD; Kim CG; Kim BG; Kim JS; Jung HC; Song IS Effect of DA-6034 and thalidomide on trinitrobenzene sulfonic acid-induced murine ileitis | 0 | 0 |
| 1082 | 0 | 0 | 1455 2002 GASTROENTEROLOGY 122(4):A498-A498 Sabate JM; Villarejo J; Lemann M; Bonnet J; Allez M; Modigliani R An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease | 0 | 0 |
| 1083 | 12 | 38 | 1456 2002 GASTROENTEROLOGY 123(1):291-300 Enomoto N; Takei Y; Hirose M; Ikejima K; Miwa H; Kitamura T; Sato N Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-alpha production | 3 | 14 |
| 1084 | 0 | 0 | 1722 2003 GASTROENTEROLOGY 124(4):A10-A10 Jin SH; Kim WH; Kim TI; Yang KM; Shin SK; Lee SK; Park SJ; Choi CH; Lee WJ Thalidomide destabilizes cyclooxygenase-2 mRNA by inhibiting p38 mitogen-activated protein kinase and cytoplasmic shuttling of HuR | 0 | 0 |
| 1085 | 0 | 0 | 1723 2003 GASTROENTEROLOGY 124(4):A336-A336 Kim YS; Kim JS; Jung HC; Song IS The effects of thalidomide on NF-R activity and TNF-production stimulated with lipopolysaccharide in a human colonic epithelial cell line ka | 0 | 0 |
| 1086 | 0 | 0 | 1724 2003 GASTROENTEROLOGY 124(4):A525-A525 Gupta P; Andrew H; Kirschner BS Thalidomide therapy for pediatric patients with refractory Crohn's disease not responding to infliximab | 0 | 0 |
| 1087 | 0 | 0 | 1904 2004 GASTROENTEROLOGY 126(4):A288-A288 Metz T; Amre D; Jones M; Chen HM; Ouyang W; Haque T; Martoni C; Prakash S Artificial cells containing thalidomide as an alternative oral therapy method for Crohn's disease | 0 | 0 |
| 1088 | 0 | 0 | 1905 2004 GASTROENTEROLOGY 126(4):A396-A397 Gordon JN; Trebble TM; Johns T; Ellis RD; Duncan HD; Goggin PM Thalidomide in the treatment of cancer cachexia: A randomised placebo controlled trial | 0 | 0 |
| 1089 | 0 | 0 | 1906 2004 GASTROENTEROLOGY 126(4):A629-A629 Simon M; Gornet JM; Plane C; Allez M; Colombel JF; Sabate JM; Cortot A; Modigliani R; Lemann M Long term efficacy and toxicity of thalidomide in Crohn's disease | 0 | 0 |
| 1090 | 8 | 14 | 527 1996 GASTROINTESTINAL ENDOSCOPY 44(6):729-731 Bellomo A; SchorrLesnick B Thalidomide treatment for idiopathic esophageal ulcers in patients with HIV | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1091 | 0 | 0 | 276 1990 GAZETTE MEDICALE 97(3):26-27 BELAICH S USE OF THALIDOMIDE IN DERMATOLOGY | 0 | 0 |
| 1092 | 1 | 33 | 116 1984 GEBURTSHILFE UND FRAUENHEILKUNDE 44(4):243-248 MUHLENSTEDT D; SCHWARZ M GYNECOLOGICAL AND ENDOCRINOLOGICAL INVESTIGATIONS IN WOMEN DAMAGED BY THALIDOMIDE | 0 | 0 |
| 1093 | 0 | 9 | 277 1990 GEBURTSHILFE UND FRAUENHEILKUNDE 50(11):899-900 SCHAEFER C; SPIELMANN H COCAINE AND PREGNANCY - SHADES OF THE THALIDOMIDE TRAGEDY | 0 | 0 |
| 1094 | 0 | 0 | 700 1998 GEBURTSHILFE UND FRAUENHEILKUNDE 58(3):M55-M58 Kosenow W Forty years ago: Thalidomide and its consequences | 0 | 0 |
| 1095 | 6 | 29 | 460 1995 GENERAL PHARMACOLOGY 26(6):1243-1247 KROGER H; KLEWER M; GRATZ R; DIETRICH A; OCKENFELS H; MIESEL R EXACERBATION OF ACETAMINOPHEN HEPATOTOXICITY BY THALIDOMIDE AND PROTECTION BY NICOTINIC-ACID AMIDE | 1 | 2 |
| 1096 | 3 | 4 | 321 1992 GENITOURINARY MEDICINE 68(6):424-425 STRAZZI S; LEBBE C; GEOFFRAY C; ABLON G; MOREL P; VEROLA O; MOLINA JM APHTHOUS ULCERS IN HIV-INFECTED PATIENTS - TREATMENT WITH THALIDOMIDE | 8 | 10 |
| 1097 | 0 | 0 | 983 2000 GESUNDHEITSWESEN 62(8-9):A87-A87 Edler B; Teige B; Nippert I Study on health-related quality of life among women with developmental retardation - Case of thalidomide victims | 0 | 0 |
| 1098 | 0 | 31 | 322 1992 GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY 230(2):140-149 STROMLAND K; MILLER MT REFRACTIVE EVALUATION IN THALIDOMIDE EMBRYOPATHY | 3 | 5 |
| 1099 | 8 | 14 | 461 1995 GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY 233(2):90-93 GUEXCROSIER Y; PITTET N; HERBORT CP THE EFFECT OF THALIDOMIDE AND SUPIDIMIDE ON ENDOTOXIN-INDUCED UVEITIS IN RATS | 5 | 6 |
| 1100 | 13 | 27 | 701 1998 GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY 236(6):461-466 Kruse FE; Joussen AM; Rohrschneider K; Becker MD; Volcker HE Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor | 39 | 57 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1101 | 7 | 33 | 810 1999 GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY 237(12):952-961 Joussen AM; Germann T; Kirchhof B Effect of thalidomide and structurally related compounds on corneal angiogenesis is comparable to their teratological potency | 4 | 8 |
| 1102 | 5 | 12 | 811 1999 GUT 45(3):463-464 Ollivier S; Bonnet J; Lemann M; Coffin JC; Modigliani R; Jian R; Bertheau P; Flejou JF Idiopathic giant oesophageal ulcer in an immunocompetent patient. The efficacy of thalidomide treatment | 1 | 2 |
| 1103 | 2 | 2 | 984 2000 GUT 47(1):156-156 Ryan J Thalidomide treatment of oesophageal ulceration | 0 | 0 |
| 1104 | 0 | 0 | 1196 2001 GUT 48:A48-A48 Khan ZH; Cole AT; Macdonald I; Pye D; Simpson L; Austin A; Freeman JG The role of thalidomide in reversing cachexia in patients with inoperable oesophageal cancer | 0 | 0 |
| 1105 | 0 | 0 | 1197 2001 GUT 48:A67-A68 Austin AS; Mahida YR; Ryder SD; Freeman JG Thalidomide but not pentoxifylline lowers portal pressure in human alcoholic cirrhosis | 0 | 0 |
| 1106 | 0 | 0 | 1198 2001 GUT 48:A89-A90 Trebble T; Johns T; Duncan HD; Goggin PM An open trial of thalidomide in refractory Crohn's colitis | 0 | 0 |
| 1107 | 0 | 0 | 1457 2002 GUT 50:A4-A4 Khan ZH; Simpson E; Cole AT; Macdonald I; Pye D; Austin A; Freeman JG Oesophageal cancer and cachexia: The effects of thalidomide on weight loss and lean body mass in a sequential (metabolic) study | 1 | 1 |
| 1108 | 13 | 36 | 1458 2002 GUT 50(2):196-200 Bauditz J; Wedel S; Lochs H Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease | 11 | 25 |
| 1109 | 6 | 21 | 1907 2004 GUT 53(4):609-612 Bauditz J; Schachschal G; Wedel S; Lochs H Thalidomide for treatment of severe intestinal bleeding | 0 | 0 |
| 1110 | 4 | 9 | 985 2000 HAEMATOLOGICA 85(10):1111-1112 Pini M; Baraldi A; Pietrasanta D; Allione B; Depaoli L; Salvi F; Levis A Low-dose thalidomide in the treatment of refractory myeloma | 11 | 19 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1111 | 0 | 2 | 1199 2001 HAEMATOLOGICA 86(4):348-348 [Anon] Thalidomide in the treatment of multiple myeloma | 0 | 0 |
| 1112 | 7 | 27 | 1200 2001 HAEMATOLOGICA 86(4):399-403 Palumbo A; Giaccone L; Bertola A; Pregno P; Bringhen S; Rus C; Triolo S; Gallo E; Pileri A; Boccadoro M Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma | 25 | 38 |
| 1113 | 5 | 21 | 1201 2001 HAEMATOLOGICA 86(4):404-408 Hus M; Dmoszynska A; Soroka-Wojtaszko M; Jawniak D; Legiec W; Ciepnuch H; Hellmann A; Wolska-Smolen T; Skotnicki A; Manko J; Polish Multiple Myeloma Study Grp Thalidomide treatment of resistant or relapsed multiple myeloma patients | 23 | 35 |
| 1114 | 17 | 33 | 1202 2001 HAEMATOLOGICA 86(4):409-413 Tosi P; Ronconi S; Zamagni E; Cellini C; Grafone T; Cangini D; Pileri SA; Baccarani M; Tura S; Cavo M Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation | 13 | 21 |
| 1115 | 0 | 0 | 1203 2001 HAEMATOLOGICA 86(4):448-448 Zappasodi P; Lorenzi A; Corso A Thalidomide in refractory myeloma patients: early changes in bone marrow cellularity | 1 | 1 |
| 1116 | 2 | 9 | 1204 2001 HAEMATOLOGICA 86(7):772-773 Pozzato G; Zorat F; Nascimben F; Comar C; Kikic F; Festini G Thalidomide therapy in compensated and decompensated myelofibrosis with myeloid metaplasia | 7 | 11 |
| 1117 | 8 | 10 | 1205 2001 HAEMATOLOGICA 86(10):1108-1109 Camba L; Peccatori J; Pescarollo A; Tresoldi M; Corradini P; Bregni M Thalidomide and thrombosis in patients with multiple myeloma | 11 | 12 |
| 1118 | 18 | 23 | 1459 2002 HAEMATOLOGICA 87(3):233-234 Tosi P; Cavo M Thalidomide in multiple myeloma: state of art | 3 | 4 |
| 1119 | 4 | 7 | 1460 2002 HAEMATOLOGICA 87(3):327-328 Corso A; Lorenzi A; Orlandi E; Astori C; Mangiacavalli S; Lazzarino M Advantages of using thalidomide for the management of patients with refractory myeloma | 3 | 4 |
| 1120 | 13 | 20 | 1461 2002 HAEMATOLOGICA 87(4):344-345 Ribatti D; Vacca A Is thalidomide a true anti-angiogenic molecule in multiple myeloma? | 1 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1121 | 14 | 22 | 1462 2002 HAEMATOLOGICA 87(4):345-346 [Anon] Inside Haematologica: caution in the use of thalidomide for treatment of hematologic disorders | 0 | 0 |
| 1122 | 15 | 35 | 1463 2002 HAEMATOLOGICA 87(4):408-414 Tosi P; Zamagni E; Cellini C; Ronconi S; Patriarca F; Ballerini F; Musto P; Di Raimondo F; Ledda A; Lauria F; Masini L; Gobbi M; Vacca A; Ria R; Cangini D; Tura S; Baccarani M; Cavo M Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma | 19 | 29 |
| 1123 | 3 | 10 | 1464 2002 HAEMATOLOGICA 87(8):884-886 Musto P; Falcone A; Sanpaolo G; Bisceglia M; Matera R; Carella AM Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes | 1 | 1 |
| 1124 | 3 | 10 | 1725 2003 HAEMATOLOGICA 88(5):597-599 Patriarca F; Sperotto A; Prosdocimo S; Geromin A; Zaja F; Fanin R Thalidomide before autologous stem cell transplantation in VAD-refractory multiple myeloma patients | 0 | 0 |
| 1125 | 4 | 10 | 1726 2003 HAEMATOLOGICA 88(8):958-960 Corso A; Lorenzi A; Zapposodi P; Invernizzi R; Vanelli L; Lazzarino M Early changes in bone marrow morphology induced by thalidomide in patients with refractory myeloma | 0 | 0 |
| 1126 | 4 | 10 | 1727 2003 HAEMATOLOGICA 88(12):1432-1433 Offidani M; Marconi M; Corvotta L; Olivieri A; Catarini M; Leoni P Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study | 0 | 1 |
| 1127 | 7 | 25 | 1908 2004 HAEMATOLOGICA 89(5):552-556 Brenne AT; Romstad LH; Gimsing P; Juliusson G; Turesson I; Romundstad P; Borset M; Sundan A; Waage A Low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma | 0 | 0 |
| 1128 | 19 | 37 | 1909 2004 HAEMATOLOGICA 89(7):826-831 Cavo M; Zamagni E; Tosi P; Cellini C; Cangini D; Tacchetti P; Testoni N; Tonelli M; De Vivo A; Palareti G; Tura S; Baccarani M First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma | 0 | 0 |
| 1129 | 9 | 32 | 1910 2004 HAEMATOLOGICA 89(7):832-836 Rosinol L; Cibeira T; Blade J; Esteve J; Aymerich M; Rozman M; Segarra M; Cid MC; Filella X; Montserrat E Extramedullary multiple myeloma escapes the effect of thalidomide | 0 | 0 |
| 1130 | 6 | 10 | 1911 2004 HAEMATOLOGICA 89(9):1141-1142 Galli M; Elice F; Crippa E; Comotti B; Rodeghiero F; Barbui T Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1131 | 2 | 66 | 85 1983 HAUTARZT 34(2):66-72 HUNZIKER T; KREBS A THALIDOMIDE IN DERMATOLOGY | 7 | 7 |
| 1132 | 0 | 14 | 86 1983 HAUTARZT 34(4):168-170 SHESKIN J; MUCKTER H; FRANKUS E SUPIDIMIDE, A NON-TERATOGENIC ANALOG OF THALIDOMIDE IN THE TREATMENT OF LEPRA REACTIONS | 2 | 2 |
| 1133 | 2 | 12 | 87 1983 HAUTARZT 34(4):175-178 VOLCPLATZER B; WOLFF K TREATMENT OF SUBACUTE CUTANEOUS LUPUS-ERYTHEMATOSUS WITH THALIDOMIDE | 3 | 6 |
| 1134 | 2 | 12 | 88 1983 HAUTARZT 34(9):435-436 KNOP J; MACHER E THALIDOMIDE IN THE TREATMENT OF CHRONIC DISCOID LUPUS-ERYTHEMATOSUS | 4 | 4 |
| 1135 | 6 | 40 | 462 1995 HAUTARZT 46(8):553-560 DALLAFIOR S; PUGIN P; CERNY T; BETTICHER D; SAURAT JH; HAUSER C A CASE OF CUTANEOUS LANGERHANS CELL GRANULOMATOSIS SUCCESSFULLY TREATED WITH 2-CHLORODEOXYADENOSINE AND THALIDOMIDE | 4 | 9 |
| 1136 | 5 | 20 | 1206 2001 HAUTARZT 52:962-965 Hoch O; Muller S; Buttner G; Mensing H Thalidomide in the treatment of cutaneous and systemic sarcoidosis | 3 | 5 |
| 1137 | 3 | 15 | 1207 2001 HAUTARZT 52:966-969 Petering H; Kiehl P; Vogelbruch M; Sticht-Groh V; Kapp A; Werfel T Chemotherapy-induced erythema nodosum leprosum: successful treatment with thalidomide | 0 | 0 |
| 1138 | 48 | 68 | 1208 2001 HAUTARZT 52(8):726-733 Kuhn A; Hefter H; Ruzicka T; Lehmann P Rediscovery of thalidomide. Successful treatment of discoid lupus erythematosus | 0 | 0 |
| 1139 | 1 | 8 | 1465 2002 HAUTARZT 53(2):150-150 Ochsendorf F; Kaufman R Thalidomide in the treatment of cutaneous and systemic sarcoidosis | 0 | 0 |
| 1140 | 2 | 2 | 1466 2002 HAUTARZT 53(2):150-151 Mensing H Thalidomide in the treatment of cutaneous and systemic sarcoidosis - Statement | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1141 | 13 | 15 | 1467 2002 HAUTARZT 53(11):744-748 Bohmeyer J; Achenbach A; Westenberger M; Stadler R Thalidomide therapy of cutaneous lupus erythematosus | 1 | 1 |
| 1142 | 5 | 34 | 528 1996 HEPATOLOGY 23(6):1616-1621 LopezTalavera JC; Cadelina G; Olchowski J; Merrill W; Groszmann RJ Thalidomide inhibits tumor necrosis factor alpha decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats | 7 | 52 |
| 1143 | 0 | 0 | 702 1998 HEPATOLOGY 28(4):460A-460A Martinez L; Lopez-Talavera JC; Martinez M; Cadelina G; Pachon JC; Esteban R; Guardia J; Groszmann RJ Amelioration of the hyperdynamic syndrome of cirrhotic rats by thalidomide. | 0 | 0 |
| 1144 | 0 | 0 | 986 2000 HEPATOLOGY 32(4):410A-410A Enomoto N; Ikejima K; Hirose M; Ishikawa M; Konno A; Matsuyama S; Shimizu H; Kitamura T; Takei Y; Sato N Thalidomide prevents alcoholic liver injury in rats through suppression of TNF-A production by Kupffer cells. | 0 | 0 |
| 1145 | 0 | 0 | 1209 2001 HEPATOLOGY 34(4):279A-279A Muriel P; Fernandez-Martinez E; Perez-Alvarez VM; Morales-Rios MS A thalidomide analog with hepatoprotective and antifibrotic properties in biliary obstruction-induced cirrhosis in the rat. | 0 | 0 |
| 1146 | 0 | 0 | 1210 2001 HEPATOLOGY 34(4):516A-516A Muriel P; Ponce S; Garcia JC Thalidomide partially prevents CCl4-induced liver cirrhosis. | 0 | 0 |
| 1147 | 0 | 0 | 1211 2001 HEPATOLOGY 34(4):517A-517A Muriel P; Garcia JC; Ponce S; Perez-Alvarez VM; Fernandez-Martinez E; Morales-Rios MS Synthesis and pharmacological evaluation of a thalidomide analog, the 3-phthalimido-3-(3,4-dimethoxyphenyl)propanoic acid in liver cirrhosis induced by bile duct ligation in the rat. | 0 | 0 |
| 1148 | 8 | 24 | 1912 2004 HISTOCHEMISTRY AND CELL BIOLOGY 122(1):27-33 Fujita K; Asami Y; Tanaka K; Akita M; Merker HJ Anti-angiogenic effects of thalidomide: expression of apoptosis-inducible active-caspase-3 in a three-dimensional collagen gel culture of aorta | 0 | 0 |
| 1149 | 19 | 40 | 987 2000 HUMAN & EXPERIMENTAL TOXICOLOGY 19(11):615-622 Teo S; Evans M; Ehrhart J; Brockman M; Allen D; Morgan M; Stirling D; Thomas S Lack of peripheral neuropathy in Beagle dogs after 53 weeks oral administration of thalidomide capsules | 0 | 0 |
| 1150 | 0 | 0 | 529 1996 IMMUNOLOGY 89:ORI27-ORI27 Marriott JB; Cookson S; Westby M; Guckian M; Dalgleish AG The effect of a thalidomide analogue on TNF-alpha/cytokine production in vitro | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1151 | 0 | 0 | 530 1996 IMMUNOLOGY 89:E51-E51 Guckian M; Marriott JB; Cookson S; Westby M; Dalgleish G Thalidomide analog 3052 reduces NK activity and PHA-induced proliferation in vitro. | 0 | 0 |
| 1152 | 15 | 32 | 812 1999 IMMUNOLOGY LETTERS 68(2-3):325-332 Rowland TL; McHugh SM; Deighton J; Ewan PW; Dearman RJ; Kimber I Selective down-regulation of T cell-and non-T cell-derived tumour necrosis factor alpha by thalidomide: comparisons with dexamethasone | 10 | 13 |
| 1153 | 38 | 52 | 813 1999 IMMUNOLOGY TODAY 20(12):538-540 Marriott JB; Muller G; Dalgleish AG Thalidomide as an emerging immunotherapeutic agent | 38 | 47 |
| 1154 | 8 | 25 | 463 1995 IMMUNOPHARMACOLOGY 31(1):109-116 SHANNON EJ; SANDOVAL F THALIDOMIDE INCREASES THE SYNTHESIS OF IL-2 IN CULTURES OF HUMAN MONONUCLEAR-CELLS STIMULATED WITH CONCANAVALIN-A, STAPHYLOCOCCAL-ENTEROTOXIN-A, AND PURIFIED PROTEIN DERIVATIVE | 34 | 37 |
| 1155 | 9 | 28 | 531 1996 IMMUNOPHARMACOLOGY 31(2-3):213-221 Geitz H; Handt S; Zwingenberger K Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade | 75 | 94 |
| 1156 | 8 | 22 | 603 1997 IMMUNOPHARMACOLOGY 35(3):203-212 Shannon EJ; Morales MJ; Sandoval F Immunomodulatory assays to study structure-activity relationships of thalidomide | 10 | 13 |
| 1157 | 8 | 21 | 604 1997 IMMUNOPHARMACOLOGY 36(1):9-15 Shannon EJ; Sandoval F; Krahenbuhl JL Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-alpha | 18 | 19 |
| 1158 | 19 | 33 | 703 1998 IMMUNOPHARMACOLOGY 40(1):11-20 Rowland TL; McHugh SM; Deighton J; Dearman RJ; Ewan PW; Kimber I Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells | 36 | 48 |
| 1159 | 5 | 17 | 814 1999 IMMUNOPHARMACOLOGY 43(1):59-64 Dunzendorfer S; Herold M; Wiedermann CJ Inducer-specific bidirectional regulation of endothelial interleukin-8 production by thalidomide | 8 | 8 |
| 1160 | 12 | 20 | 988 2000 IMMUNOPHARMACOLOGY 46(2):175-179 Shannon E; Aseffa A; Pankey G; Sandoval F; Lutz B Thalidomide's ability to augment the synthesis of IL-2 in vitro in HIV-infected patients is associated with the percentage of CD4+cells in their blood | 8 | 8 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1161 | 5 | 34 | 406 1994 IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY 16(4):717-729 SHANNON EJ; HOWE RC; MCLEAN K; HASTINGS RC THALIDOMIDE DOES NOT PERTURB CD2, CD4, CD5, CD8, HLA-DR, OR HLA-A, HLA-B, HLA-C MOLECULES IN-VITRO ON THE MEMBRANES OF CELLS WITH IMMUNE POTENTIAL | 5 | 5 |
| 1162 | 3 | 22 | 532 1996 IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY 18(1):59-72 Shannon EJ; Sandoval F Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-alpha by mononuclear cells | 21 | 24 |
| 1163 | 5 | 35 | 605 1997 IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY 19(3):313-326 Aseffa A; Dietrich MA; Shannon EJ Effect of thalidomide on apoptosis of lymphocytes and neutrophils | 4 | 5 |
| 1164 | 10 | 43 | 533 1996 INFLAMMATION 20(2):203-215 Kroger H; Miesel R; Dietrich A; Ohde M; Rajnavolgyi E; Ockenfels H Synergistic effects of thalidomide and poly(ADP-ribose) polymerase inhibition on type II collagen-induced arthritis in mice | 1 | 12 |
| 1165 | 2 | 29 | 815 1999 INFLAMMATION 23(6):495-505 Gallily R; Kipper-Galperin M; Brenner T Mycoplasma fermentans-induced inflammatory response of astrocytes: Selective modulation by aminoguanidine, thalidomide, pentoxifylline and IL-10 | 1 | 4 |
| 1166 | 3 | 20 | 989 2000 INFLAMMATION 24(4):347-356 Lindsay L; Oliver SJ; Freeman SL; Josien R; Krauss A; Kaplan G Modulation of hyperoxia-induced TNF-alpha expression in the newborn rat lung by thalidomide and dexamethasone | 1 | 5 |
| 1167 | 18 | 36 | 1212 2001 INFLAMMATION 25(2):91-96 Belo AV; Ferreira MAND; Bosco AA; Machado RDP; Andrade SP Differential effects of thalidomide on angiogenesis and tumor growth in mice | 0 | 2 |
| 1168 | 8 | 21 | 606 1997 INFLAMMATION RESEARCH 46(10):392-397 Schneider J; Bruckmann W; Zwingenberger K Extravasation of leukocytes assessed by intravital microscopy: Effect of thalidomide | 5 | 13 |
| 1169 | 2 | 2 | 990 2000 INFLAMMATORY BOWEL DISEASES 6(2):152-153 Katz JA Thalidomide for Crohn's disease: High dose, low dose, or "no doze" at all? Comment | 1 | 1 |
| 1170 | 6 | 15 | 1728 2003 INTERNAL MEDICINE 42(7):550-551 Dan K Thalidomide as a targeted therapy for multiple myeloma | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1171 | 5 | 10 | 1729 2003 INTERNAL MEDICINE 42(7):605-608 Hayashi T; Yamaguchi I; Saitoh H; Takagi M; Nonaka Y; Nomura T Thalidomide treatment for immunoglobulin D multiple myeloma in a patient on chronic hemodialysis | 1 | 2 |
| 1172 | 6 | 14 | 534 1996 INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY 111(1):13-17 SantosMendoza T; FavilaCastillo L; Oltra A; Tamariz J; Labarrios F; EstradaParra S; EstradaGarcia I Thalidomide and its metabolites have no effect on human lymphocyte proliferation | 7 | 9 |
| 1173 | 2 | 25 | 704 1998 INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY 116(1):60-66 Partida-Sanchez S; Favila-Castillo L; Pedraza-Sanchez S; Gomez-Melgar M; Saul A; Estrada-Parra S; Estrada-Garcia I IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment | 9 | 13 |
| 1174 | 13 | 23 | 1213 2001 INTERNATIONAL IMMUNOPHARMACOLOGY 1(1):49-61 Rowland TL; McHugh SM; Deighton J; Ewan PW; Dearman RJ; Kimber I Differential effect of thalidomide and dexamethasone on the transcription factor NF-kappa B | 5 | 8 |
| 1175 | 11 | 22 | 1468 2002 INTERNATIONAL IMMUNOPHARMACOLOGY 2(8):1143-1153 Shannon EJ; Sandoval FG Thalidomide can costimulate or suppress CD4(+) cells' ability to incorporate [H-3]-thymidine-dependence on the primary stimulant | 4 | 4 |
| 1176 | 16 | 42 | 1730 2003 INTERNATIONAL IMMUNOPHARMACOLOGY 3(10-11):1447-1456 Karrow NA; Guo TL; Zhang LX; McCay JA; Musgrove DL; Peachee VL; Germolec DR; White KL Thalidomide modulation of the immune response in female B6C3F1 mice: a host resistance study | 0 | 1 |
| 1177 | 0 | 0 | 1469 2002 INTERNATIONAL JOURNAL OF CANCER :104-104 Hatjiharissi E; Gerotziafas G; Papaioannou M; Bakaloudi V; Tokmaktsis A; Kaloutsi V; Christakis J; Zervas K Efficacy and tolerability of combination thalidomide-dexamethasone in multiple myeloma patients with refractory disease | 0 | 0 |
| 1178 | 0 | 0 | 1470 2002 INTERNATIONAL JOURNAL OF CANCER :336-337 Chen LT; Chao Y; Yao TJ; Huang JD; Chang JY; Chin YH; Chuang TR; Reed E; Whang-Peng J; Liu TW Phase I and pharmacokinetic studies of oral thalidomide in advanced hepatocellular carcinoma | 0 | 0 |
| 1179 | 0 | 0 | 1471 2002 INTERNATIONAL JOURNAL OF CANCER :402-402 Hatjiharissi E; Gerotziafas G; Hatjileontis C; Galaktidou G; Bakaloudi V; Papaioannou M; Kaloutsi V; Kortsaris A; Christakis J; Zervas K Study of neoangiogenesis and cytokine serum levels in patients with refractory multiple myeloma treated with thalidomide-dexamethasone | 0 | 0 |
| 1180 | 5 | 30 | 1913 2004 INTERNATIONAL JOURNAL OF CANCER 110(2):260-265 Kedar I; Mermershtain W; Ivgi H Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1181 | 12 | 24 | 1214 2001 INTERNATIONAL JOURNAL OF CLINICAL PRACTICE 55(9):627-631 Diggle GE Thalidomide: 40 years on | 7 | 10 |
| 1182 | 0 | 2 | 16 1981 INTERNATIONAL JOURNAL OF DERMATOLOGY 20(3):220-220 JOPLING WH THALIDOMIDE | 0 | 0 |
| 1183 | 0 | 0 | 17 1981 INTERNATIONAL JOURNAL OF DERMATOLOGY 20(3):220-220 SHESKIN J THALIDOMIDE - REPLY | 0 | 0 |
| 1184 | 22 | 61 | 117 1984 INTERNATIONAL JOURNAL OF DERMATOLOGY 23(9):598-602 GROSSHANS E; ILLY G THALIDOMIDE THERAPY FOR INFLAMMATORY DERMATOSES | 55 | 62 |
| 1185 | 11 | 24 | 150 1985 INTERNATIONAL JOURNAL OF DERMATOLOGY 24(2):131-134 NAAFS B; FABER WR THALIDOMIDE THERAPY - AN OPEN TRIAL | 27 | 36 |
| 1186 | 2 | 2 | 151 1985 INTERNATIONAL JOURNAL OF DERMATOLOGY 24(9):616-616 GROSSHANS EM DISCOID LUPUS-ERYTHEMATOSUS - THALIDOMIDE OR VITAMIN-E | 0 | 0 |
| 1187 | 1 | 4 | 152 1985 INTERNATIONAL JOURNAL OF DERMATOLOGY 24(9):616-616 AYRES S DISCOID LUPUS-ERYTHEMATOSUS - THALIDOMIDE OR VITAMIN-E | 0 | 1 |
| 1188 | 1 | 6 | 323 1992 INTERNATIONAL JOURNAL OF DERMATOLOGY 31(8):599-600 BERNAL JE; DURAN MM; LONDONO F; UMANA A CELLULAR IMMUNE EFFECTS OF THALIDOMIDE IN ACTINIC PRURIGO | 8 | 13 |
| 1189 | 48 | 74 | 607 1997 INTERNATIONAL JOURNAL OF DERMATOLOGY 36(12):881-887 Calderon P; Anzilotti M; Phelps R Thalidomide in dermatology. New indications for an old drug | 22 | 27 |
| 1190 | 6 | 10 | 816 1999 INTERNATIONAL JOURNAL OF DERMATOLOGY 38(1):76-77 Pizarro A; Garcia-Tobaruela A; Herranz P; Pinilla J Thalidomide as an inhibitor of tumor necrosis factor-alpha production: a word of caution | 1 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1191 | 16 | 22 | 991 2000 INTERNATIONAL JOURNAL OF DERMATOLOGY 39(3):218-222 Kyriakis KP; Kontochristopoulos GJ; Panteleos DN Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus | 10 | 17 |
| 1192 | 18 | 27 | 992 2000 INTERNATIONAL JOURNAL OF DERMATOLOGY 39(5):383-388 Walchner M; Meurer M; Plewig G; Messer G Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus | 16 | 27 |
| 1193 | 11 | 39 | 1731 2003 INTERNATIONAL JOURNAL OF DERMATOLOGY 42(5):372-375 Alfadley A; Al-Hawsawi K; Thestrup-Pedersen K; Al-Aboud K Treatment of prurigo nodularis with thalidomide: a case report and review of the literature | 0 | 0 |
| 1194 | 8 | 12 | 1914 2004 INTERNATIONAL JOURNAL OF DERMATOLOGY 43(9):682-684 Cunha PR; de Oliveira JR; Salles MJ; Jamora J; Bystryn JC Pemphigus vulgaris with involvement of the cervix treated using thalidomide therapy | 0 | 0 |
| 1195 | 4 | 24 | 817 1999 INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY 80(1):11-16 Arrieta O; Ortiz-Reyes A; Rembao D; Calvillo M; Rivera E; Sotelo J Protective effect of pentoxifylline plus thalidomide against septic shock in mice | 4 | 8 |
| 1196 | 27 | 44 | 1472 2002 INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY 83(2):99-104 Arrieta O; Guevara P; Tamariz J; Rembao D; Rivera E; Sotelo J Antiproliferative effect of thalidomide alone and combined with carmustine against C6 rat glioma | 1 | 3 |
| 1197 | 7 | 20 | 1473 2002 INTERNATIONAL JOURNAL OF HEMATOLOGY 76(4):365-369 Miller S; Sharda S; Rodrigue J; Mehta P Thalidomide in chronic graft-versus-host disease after stem cell transplantation: Effects on quality of life | 0 | 0 |
| 1198 | 6 | 40 | 1732 2003 INTERNATIONAL JOURNAL OF HEMATOLOGY 78(5):443-449 Ural AU; Yilmaz MI; Avcu F; Pekel A; Zerman M; Nevruz O; Sengul A; Yalcin A The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide | 0 | 2 |
| 1199 | 17 | 25 | 1915 2004 INTERNATIONAL JOURNAL OF HEMATOLOGY 79(3):283-288 Hattori Y; Kakimoto T; Okamoto S; Sato N; Ikeda Y Thalidomide-induced severe neutropenia during treatment of multiple myeloma | 0 | 0 |
| 1200 | 9 | 19 | 1916 2004 INTERNATIONAL JOURNAL OF HEMATOLOGY 79(4):364-368 Okikawa Y; Sakai A; Takimoto Y; Noda M; Imagawa J; Katayama Y; Kuroda Y; Okita H; Fujimura K; Kimura A Progressive myeloma after thalidomide therapy in a patient with immature phenotype of myeloma (plasma) cells | 0 | 0 |